Nexlizet FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved February 26, 2020)
Brand name: Nexlizet
Generic name: bempedoic acid and ezetimibe
Dosage form: Tablets
Company: Esperion Therapeutics
Treatment for: High Cholesterol, Familial Heterozygous
Nexlizet (bempedoic acid and ezetimibe) is an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor combination indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Development Timeline for Nexlizet
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.